Results 71 to 80 of about 6,725 (159)

Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review

International Journal of Women's Health
Anna Gonzalez,1 Quinn Kistenfeger,2 Casey M Cosgrove1 1Division of Gynecologic Oncology; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH, USA; 2Division of Obstetrics & Gynecology;
Gonzalez A, Kistenfeger Q, Cosgrove CM
doaj  

NIRAPARIB: AN OVERVIEW

The most common gynaecological cancer-related cause of death is ovarian cancer.
openaire   +1 more source

Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study. [PDF]

ESMO Real World Data Digit Oncol
Fagotti A, Frenel JS, Saint-Ghislain M, Lim JT, Calderón Boyle TA, Golembesky AK, Hogg C, Arnold K, Braicu EI.   +8 more
europepmc   +1 more source

BCLX_L blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer. [PDF]

Signal Transduct Target Ther
Venkatachalam A, Strathman AR, Hou X, Correia C, Meng XW, McGehee CD, Balczewski EA, Duffield LN, Rossman OK, Wong C, Dai H, Hurley RM, Wagner JM, Singh S, Flatten KS, Peterson KL, Schneider PA, De Lorenzo SB, Larson MC, Oberg AL, Wahner Hendrickson AE, Wu X, Pandey A, Li H, Weroha SJ, Kaufmann SH.   +25 more
europepmc   +1 more source

ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination-proficient high-grade serous ovarian cancer. [PDF]

Cancer Cell Int
Cheng S, Li J, Ling Y, Luo J, Zhou D, Mao T, Luo T, Tu Y, Du J, Zhou M, Qin Q, Ji Y.   +11 more
europepmc   +1 more source

Synthesis and Preliminary Biological Evaluation of a Structurally Modified Niraparib-Based PARP-Targeted PET Tracer for Tumor Imaging. [PDF]

ACS Omega
Deng J, You D, Zhang C, Tian C, Liu X, Dou X, Zhao Y, Chen Y.   +7 more
europepmc   +1 more source

The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy. [PDF]

Clin Cancer Res
Robinson HMR, Grinkevich V, Majithiya JB, Mann SE, McWhirter C, Rajendra E, Ranzani M, Stockley ML, Costales P, Davis OA, Elinati E, Galbiati A, Geo L, Toste Rêgo A, Mason B, Armstrong L, Grande D, Neves J, Roy Luzarraga M, Cooper H, Edwardes L, Konstantinou T, van de Ven M, Moises da Silva A, Moser SC, Charles MD, Finch H, Higgins GS, Boulton SJ, Jonkers J, Martin NMB, Heald RA, Smith GCM.   +32 more
europepmc   +1 more source

Synchronous Ovarian and Cervical Malignancies: A Case Report of Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and Niraparib Maintenance. [PDF]

Int J Womens Health
Lv X, Tang L, Ma Y, Zhou L.
europepmc   +1 more source

A Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance. [PDF]

Chirality
Kondaveti PK, Douglas P, Raghunadh A, Kalyanaraman L.   +3 more
europepmc   +1 more source

Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC). [PDF]

Oncologist
Kasi A, Al-Rajabi RMT, Baranda JC, Saeed A, Dai J, Chalise P, Weir S, Sear B, Carroll E, Bradbury S, Tripathi A, Hyter S, Beeki V, McKittrick RJ, Kumer S, Schmitt T, Soper S, Godwin AK, Sun W.   +18 more
europepmc   +1 more source